Colli-Pee standardized first-void urine collection.
Colli-Pee is a patented, award-winning, CE-labelled & FDA-listed device to efficiently and hygienically capture first-void urine (first catch of the urine flow; first 20ml). Colli-Pee is a user-friendly and compact device which is suited for postal delivery. It can be used by all genders.
Collection of first-void urine allows for improved detection of:
- Biomarkers for early stage diagnosis and monitoring of (urological) cancers.
- Sexually transmitted infections (STIs) like Chlamydia, Gonorrhea, Mycoplasma, Trichomonas, and Zikavirus.
- Human Papilloma Virus (HPV), a virus able to cause cervical cancer.
Find out more!
Aim: Use of self-sampling devices for detection of HPV
Partners: IPH Belgium, University of Antwerp, Abbott, Roche, BD, Cepheid, Seegene, Fujirebio, Novosanis
A total of 500 women, referral population will be included through colposcopy clinics in Belgium (Tienen, Brussels, Ghent and Antwerp). Women will be asked to collect different self-samplers, including Evalyn® brush or Qvintip (50-50), Colli-Pee™ FV-5000 series (UCM preservative), and FLOQSwab™. Additionally a clinician-based sample will be taken.
Assays: COBAS4800 & 6800 (Roche) & Anyplex (Seegene) & Innolipa (Fujirebio) & Onclarity (BD)µ
Status: Inclusions ongoing
Self-samples and clinician-based samples will be analyzed for the presence of HPV.